AlphAIAlphAI — Financial news for AI agents
tradingview.com$AURX

Nuo Therapeutics 3Q 2026: Revenue $1.87M, EPS ($0.01) — 10-Q Summary

Nuo Therapeutics reported 3Q 2026 revenue of $1.87M, up 81% YoY, with a net loss of $424.93K. Gross margin improved to 64% from 61%. Growth was driven by increased sales of Aurix and Smith+Nephew products, though Aurix faced a temporary supply disruption. The company received a $250,000 milestone payment for expanded reimbursement coverage.

Original reporting
tradingview.com
Published Nov 13, 2026, 10:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 10:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Nuo Therapeutics 3Q 2026: Revenue $1.87M, EPS ($0.01) — 10-Q Summary — source image
Source · tradingview.com
Decision brief

The 30-second read

$AURXBullishMed
01

Why it matters

The earnings release provides fresh data for traders to reassess valuation.

02

Market read

New quarterly numbers for a micro‑cap biotech may trigger modest price movement.

03

What to watch

Supply‑chain interruption of Aurix could recur, limiting upside.

Relevance 6/10Novelty 7/10Timing: after-hours today

Background

Nuo Therapeutics filed its 10‑Q for Q3 2026, highlighting revenue growth and a milestone payment.

Company-level read

Ticker impact

$AURXBullishHigh confidence
Context

Nuo Therapeutics reported Q3 2026 revenue of $1.87M, an 81% YoY increase, and a narrowed net loss.

Expected impact

potential modest upside as revenue growth exceeds expectations

Evidence & confidence

Revenue rose sharply while gross margin improved, indicating better operating leverage.

Market effects

Sector

Positive signal for biotech devices and surgical supplies sector.

Regional

Limited to US small‑cap biotech market.

Global

Low global relevance.

Counterpoint

What could challenge this read

Revenue base remains tiny; growth may not translate to meaningful price move.

Key entities

  • company
    Nuo Therapeutics

    Biotech firm developing surgical hemostasis products.

Read at source← All news

Related articles

$AURXMed

NUO THERAPEUTICS ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Nuo Therapeutics, Inc. (AURX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99 8285 El Rio, Suite 190 Houston, TX 77054 Phone 833.298.6633 NUO THERAPEUTICS ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Differentiated Autologous PRP Remains Well-Positioned for Attractive Long-Term Growth Houston, TX – August 17, 2026

SEC EDGAR 8-K
$NMAXMed

Why Newsmax Stock Popped on Friday

Newsmax (NMAX) shares rose 31% after reporting Q3 revenue of $69M, up 52.5% YoY, and net income of $15.2M. The company cited strong audience engagement and growth in high-margin revenue streams. CEO Christopher Ruddy expects continued growth ahead of the presidential election.

finance.yahoo.com
$LUNRMed

What Is Driving Intuitive Machines Stock?

Intuitive Machines (LUNR) shares rose 7.0% on Nov 12, 2026, after reporting Q3 revenue of $269M, beating estimates. The company's loss of $0.10 per share met expectations, while gross margin improved to 26%. Free cash flow turned positive at $33M, a company record. Management raised full-year revenue guidance to $920M-$950M. The stock's performance contrasted with broader industry declines.

finance.yahoo.com
$RMIXMedAI 8/10

Suncrete (RMIX) Q3 2026 Earnings Call Transcript

Suncrete (RMIX) reported Q3 2026 revenue of $141M, up 45% QoQ and 163% YoY. Adjusted EBITDA rose 66% QoQ to $22.4M. The company lowered its full-year outlook due to residential construction weakness but remains confident in long-term demand. Acquisition integration is progressing, with North Texas showing margin improvement. Suncrete expects $200M-$250M revenue from 2026 acquisitions in 2027. The company has $206.5M in total liquidity.

finance.yahoo.com
$CLLSMed

Cellectis SA (CLLS) (Q3 2026) Earnings Call Highlights: Strategic Shift to Gene

Cellectis SA (CLLS) discussed its strategic shift to gene editing during its Q3 2026 earnings call. Management highlighted the selection of APOC3 over ANGPTL3 for triglyceride reduction, with plans to start Phase 1 dosing by end-2027. The company reported $149M in cash as of September 30, 2026, with a runway into H2 2028. Revenue decreased to $19.9M from $67.4M YoY, while R&D expenses increased to $108.8M from $69.1M, driven by the AstraZeneca collaboration.

finance.yahoo.com
$YTRAMed

Yatra Online Inc (YTRA) (Q2 2027) Earnings Call Highlights: Air and Corporate Travel

Yatra Online (YTRA) reported Q2 2027 revenue from operations down 39% YoY to INR2,136M (~$22M) due to lower MICE volumes. Gross margin stayed flat at INR1,255M (~$13M). Adjusted EBITDA swung to negative INR32M (~negative $0.3M). CEO Gupta noted MICE recovery signs, TravelPro and Recap initiatives progress, and AI efficiency gains. Standalone hotels grew 20% YoY. H1 FY27 revenue declined 28% YoY to INR4,015M (~$42M).

finance.yahoo.com